PART I Company Overview We are a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor, RYTELO (imetelstat), harnesses Nobel Prize winning science in a treatment that scientific evidence suggests reduces proliferation of malignant cells, allowing production of new healthy cells, which we believe drives differentiated clinical benefits, potentially altering the underlying course and modifying the disease o...
Q2 FY2026 — expected 2026-08-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-02 | 2025-12-31 | 0000886744-26-000008 | EDGAR | 95K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-027982 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0000950170-24-022056 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008437 | EDGAR | — |
| 2022-03-10 | 2021-12-31 | 0001564590-22-009627 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001564590-21-012493 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001564590-20-010449 | EDGAR | — |
| 2019-03-07 | 2018-12-31 | 0001564590-19-006759 | EDGAR | — |
| 2018-03-16 | 2017-12-31 | 0001564590-18-006051 | EDGAR | — |
| 2017-03-01 | 2016-12-31 | 0001047469-17-001123 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-07 | 2025-09-30 | 0000886744-25-000071 | EDGAR | 60K words |
| 2025-08-06 | 2025-06-30 | 0000886744-25-000052 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0000886744-25-000010 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123282 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093950 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0000950170-24-052074 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0000950170-23-057760 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037931 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020853 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022712 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016839 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0000950170-22-008472 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001193125-26-125151 | EDGAR | 1K words |
| 2026-02-25 | 0001193125-26-068523 | EDGAR | — |
| 2026-01-12 | 0000886744-26-000003 | EDGAR | — |
| 2026-01-06 | 0001193125-26-003388 | EDGAR | — |
| 2025-12-16 | 0000886744-25-000074 | EDGAR | — |
| 2025-11-05 | 0000886744-25-000068 | EDGAR | — |
| 2025-10-14 | 0001628280-25-044862 | EDGAR | — |
| 2025-08-06 | 0000886744-25-000054 | EDGAR | — |
| 2025-08-06 | 0000886744-25-000048 | EDGAR | — |
| 2025-05-27 | 0000886744-25-000032 | EDGAR | — |
349 total filings indexed. 317 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000886744 |
| Ticker | GERN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.geron.com |
| Listed | 1996-07-31 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report